Inventor · disambiguated record
Rama Krishna Narla
Also filed as: NARLA RAMA · NARLA RAMA K · NARLA RAMA KRISHNA
34 granted patents·17 pending applications·349 citations·filing 1999–2025
97Inventor score
Files withCELGENE CORP14PARKER HUGHES INST14SIGNAL PHARM LLC10PERRIN-NINKOVIC SOPHIE3SIGNAL PHARMACEUTICAL LLC3
Top patents by PatentIndex Score
51 records- 0196US11149007B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Oct 19, 2021·14 cites·41 claims
- 0296US8492381B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Jul 23, 2013·44 cites·21 claims
- 0396US8110578B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2009·Granted Feb 7, 2012·67 cites·28 claims
- 0496US6358962B26,7-Dimethoxyquinazolines and therapeutic use thereofPARKER HUGHES INST·Filed 2001·Granted Mar 19, 2002·40 cites·11 claims
- 0594US11325889B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted May 10, 2022·11 cites·35 claims
- 0693US11873283B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 16, 2024·2 cites·34 claims
- 0793US8507492B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Aug 13, 2013·22 cites·20 claims
- 0892US9493466B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2012·Granted Nov 15, 2016·7 cites·5 claims
- 0991US6552027B2Quinazolines for treating brain tumorPARKER HUGHES INST·Filed 2001·Granted Apr 22, 2003·35 cites·2 claims
- 1090US11666579B2Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Jun 6, 2023·2 cites·21 claims
- 1183US11390617B2Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Jul 19, 2022·1 cites·31 claims
- 1283US9428509B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted Aug 30, 2016·6 cites·32 claims
- 1383US9346812B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted May 24, 2016·6 cites·30 claims
- 1482US9937170B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2016·Granted Apr 10, 2018·1 cites·5 claims
- 1582US2024207255A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2024·Application pending·0 cites
- 1681US12404241B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Sep 2, 2025·0 cites·16 claims
- 1780US2023119470A1PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAYSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 1880US2024400548A1Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2024·Application pending·0 cites
- 1979US6638939B26,7-dimethoxyquinazolines and therapeutic use thereofPARKER HUGHES INST·Filed 2001·Granted Oct 28, 2003·8 cites·12 claims
- 2078US12396995B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2023·Granted Aug 26, 2025·0 cites·34 claims
- 2178US2025352551A1Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2025·Application pending·0 cites
- 2277US12103923B2Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2022·Granted Oct 1, 2024·0 cites·23 claims
- 2377US12029738B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·23 claims
- 2476US12178822B2Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dionCELGENE CORP·Filed 2023·Granted Dec 31, 2024·0 cites·26 claims
- 2574US2022273650A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2021·Application pending·0 cites
- 2673US6251882B1Alkyl ketones as potent anti-cancer agentsPARKER HUGHES INST·Filed 1999·Granted Jun 26, 2001·16 cites·22 claims
- 2772US6316454B16,7-Dimethoxy-4-anilinoquinazolinesPARKER HUGHES INST·Filed 1999·Granted Nov 13, 2001·24 cites·15 claims
- 2871US11166950B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Nov 9, 2021·0 cites·5 claims
- 2971US2023338370A1Treatment of Cancer with TOR Kinase InhibitorsSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 3068US11583536B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2020·Granted Feb 21, 2023·0 cites·41 claims
- 3168US6797721B2Phorboxazole derivatives for treating cancerPARKER HUGHES INST·Filed 2002·Granted Sep 28, 2004·4 cites·11 claims
- 3268US6258820B1Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolinesPARKER HUGHES INST·Filed 1999·Granted Jul 10, 2001·17 cites·36 claims
- 3367US6262053B1Melamine derivatives as potent anti-cancer agentsPARKER HUGHES INST·Filed 1999·Granted Jul 17, 2001·22 cites·21 claims
- 3461US7038049B2Haloanilino quinazolines and therapeutic use thereofPARKER HUGHES INST·Filed 2004·Granted May 2, 2006·0 cites·11 claims
- 3558US9937169B2Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapySIGNAL PHARM LLC·Filed 2014·Granted Apr 10, 2018·0 cites·4 claims
- 3657US2004039002A16,7-Dimethoxyquinazolines and therapeutic use thereofPARKER HUGHES INST·Filed 2003·Application pending·0 cites
- 3756US10391092B2Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapySIGNAL PHARM LLC·Filed 2018·Granted Aug 27, 2019·0 cites·9 claims
- 3853US9795607B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2016·Granted Oct 24, 2017·0 cites·33 claims
- 3953US2007191343A14-((4-(2-Azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewithSAKATA STEVEN T·Filed 2006·Application pending·0 cites
- 4053US2009099178A1Indazole compounds and methods of use thereofBHAGWAT SHRIPAD S·Filed 2008·Application pending·0 cites
- 4152US2007123511A1Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancerSAKATA STEVEN T·Filed 2006·Application pending·0 cites
- 4251US2005119322A1Phorboxazole derivatives for treating cancerUNIV MINNESOTA·Filed 2004·Application pending·0 cites
- 4350US2013245027A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 4449US2005096473A1Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis inductionPARKER HUGHES INST·Filed 2004·Application pending·0 cites
- 4548US2006004043A1Indazole compounds and methods of use thereofBHAGWAT SHRIPAD S·Filed 2004·Application pending·0 cites
- 4648US2005009876A1Indazole compounds, compositions thereof and methods of treatment therewithFiled 2003·Application pending·0 cites
- 4748US2005107386A1Methods of treating diseases and disorders by targeting multiple kinasesFiled 2004·Application pending·0 cites
- 4844US6794541B2Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis inductionPARKER HUGHES INST·Filed 2001·Granted Sep 21, 2004·0 cites·1 claims
- 4943US2014113904A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 5041US6878388B1Vanadium compounds for treating proliferative cell disordersPARKER HUGHES INST·Filed 2000·Granted Apr 12, 2005·0 cites·34 claims
Showing the top 50 of 51 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →